Importantly, a dose-response tracking experiment reveals an elevated TGFα serum level in chemoresistant HNSCC patients during and after receiving NACT treatment, while administration of anti-EGFR cetuximab rescues chemotherapeutic response in tumors derived from the co-injection of cancer cells and rCAFs in vivo. This evidence concerns the gene EGFR and cancer.